Business Wire

PGE selects ADVA’s assured PNT solution for critical smart grid infrastructure

18.8.2021 10:00:00 EEST | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that Portland General Electric (PGE) is deploying Oscilloquartz PTP grandmaster clock technology as it upgrades to packet-based synchronization and protects its network against GNSS vulnerabilities and cyberattacks, while conforming to PNT Executive Order 13905. PGE, one of the largest power utilities in the Western United States, is using ADVA scalable timing solution to not only enable a smooth transition from legacy synchronization and ensure new levels of accuracy, reliability and resiliency but also to timestamp data and control grid substations at the edge. With multi-band GNSS receivers and AI-powered threat detection, ADVA’s assured PNT (aPNT) platform helps maintain resilient timing, even in challenging circumstances such as deliberate jamming and spoofing attacks. Easy to install and operate, the solution also provides multi-source backup, including PTP network timing and in-device holdover oscillators for when GNSS signals are unavailable or disrupted.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005033/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s aPNT platform is key for the development of PGE’s critical network infrastructure (Photo: Business Wire)

“Precise and resilient synchronization is increasingly vital in the power industry. By harnessing new time-sensitive applications and building smarter energy infrastructure, we can offer even more to customers across our region. ADVA’s Oscilloquartz technology will be a key tool as we continue to lead the way to a more sustainable and affordable energy future for our community,” said John Lozano, senior telecommunications engineer, PGE. “ADVA’s OSA 5420 Series supports our existing synchronization services while also enabling packet time distribution all the way to the edge of our network. With its GPS jamming and spoofing detection, it provides a robust yet cost-efficient defense against cyber threats. It also makes maintenance and configuration simple with an easy-to-operate web GUI and customizable database.”

PGE’s new timing infrastructure will distribute stable and accurate frequency, phase and time-of-day information between its power infrastructure data points, including PMUs, IEDs and substation LAN IEC 61850 communications, supporting rapid decision-making and automated assurance. The solution is built on the OSA 5410 and OSA 5420 Series of edgeSync+™ grandmaster clocks. It features multi-band, multi-constellation GNSS receivers and supports multiple PTP profiles, including substation power and core telecom backup sync, while also allowing conversion between them and supporting legacy interfaces. The products are part of ADVA’s new aPNT platform, integrating threat detection, multi-source backup and ADVA’s intelligent Ensemble Sync Director, as the new trusted standard for PNT service assurance, control and visibility.

“We’re proud that PGE is leveraging our synchronization technology and the support of our team as it makes the shift to next-generation timing. With its compact and environmentally friendly design, our technology will bring assured and protected synchronization to the edge of PGE’s network, enhancing efficiency and enabling it to take advantage of emerging smart grid applications,” commented John Scherzinger, SVP, sales, Americas, ADVA. “PGE’s highly resilient new solution will deliver the nanosecond accuracy and the levels of timing availability required by tomorrow’s power utilities. It features aPNT capabilities, our centralized GNSS monitoring and assurance tool for predictive maintenance, and our multi-band receivers with the power to compensate for ionospheric delay variations and protect against GNSS vulnerabilities.”

Further information on ADVA’s aPNT platform is available in this sync guide: https://adva.li/apnt-sync-guide.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye